Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL701 in Relapsed/Refractory AML or MDS-EB-2
NCT05703542Phase 1Active, not recruiting
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talabostat in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts-2 (MDS-EB-2). Primary endpoints: Maximum Tolerated Dose up to 35 days and Number of Participants with treatment related Adverse Events per CTCAE 5.0. Started Feb 2023; status: active, not recruiting.
02
Drugs
talabostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Beyond the preview
Go deeper on NCT05703542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703542.